Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01242774 | Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01613976 | A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 |
| clinicaltrials |
| NCT00067028 | Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) | completed | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01371656 | Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation | completed | Phase 3 | 624 | Children's Oncology GroupNETWORK | 2 | Dec 7, 2020 | clinicaltrials |
| NCT02181478 | Intra-Osseous Co-Transplant of UCB and hMSC | completed | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT02046122 | Adoptive Transfer of Haplo-identical DLI for AML and MDS | completed | Phase 1 / Phase 2 | 19 | Duke UniversityOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02750995 | Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML(AZACTA) | completed | Phase 1 | 5 | Daniel El FassiOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT02799147 | GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | completed | Phase 1 / Phase 2 | 27 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03176849 | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | completed | Phase 4 | 49 | Phoenix Children's HospitalOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT01943682 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | completed | Phase 1 | 27 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT04617145 | Aerobic Versus Resistive Training on Functional Capacity in Acute Myeloid Leukemia | completed | N/A | 60 | Cairo UniversityOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT03338348 | Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 | completed | Phase 2 | 9 | University of UlmOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01816230 | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | completed | Phase 1 / Phase 2 | 36 | Gamida Cell ltdINDUSTRY | 5 | Oct 22, 2020 | clinicaltrials |
| NCT02410252 | Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies | completed | N/A | 25 | Massachusetts General HospitalOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02029950 | Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02458235 | Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | completed | Phase 2 | 17 | University of California, San FranciscoOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02763475 | NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents | completed | Phase 2 | 7 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01910012 | PH 2 ADI-PEG 20 Acute Myeloid Leukemia | completed | Phase 2 | 43 | Polaris GroupINDUSTRY | 2 | Oct 1, 2020 | clinicaltrials |
| NCT01246622 | Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT04562818 | Results From a Mexican Acute Promyelocytic Leukemia.(Mexico APL) | completed | — | 360 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00809250 | Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation | completed | Phase 1 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | completed | Phase 2 | 213 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01869777 | Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia | completed | N/A | 102 | Wake Forest University Health SciencesOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03820908 | Bisantrene for Relapsed /Refractory AML | completed | Phase 2 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Aug 7, 2020 | clinicaltrials |
| NCT01830361 | Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML(MIDOKIT) | completed | Phase 2 | 18 | Technische Universität DresdenOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT02927106 | Beat AML Core Study | completed | — | 22 | University of FloridaOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT03526926 | A Post-Marketing Observational Study of VYXEOS™ | completed | — | 52 | Jazz PharmaceuticalsINDUSTRY | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT01235572 | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | completed | Phase 2 | 200 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT00822393 | Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) | completed | Phase 3 | 570 | medac GmbHINDUSTRY | 6 | Jul 30, 2020 | clinicaltrials |
| NCT02273102 | Study of TCP-ATRA for Adult Patients With AML and MDS(TCP-ATRA) | completed | Phase 1 | 17 | University of MiamiOTHER | 1 | Jul 21, 2020 | clinicaltrials |
| NCT02405338 | DC Vaccination for Post-remission Therapy in AML | completed | Phase 1 / Phase 2 | 20 | Medigene AGINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03125239 | Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | Jacqueline Garcia, MDOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | completed | Phase 3 | 49 | Mesoblast, Ltd.INDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT01477606 | Protocol in Acute Myeloid Leukemia With FLT3-ITD | completed | Phase 2 | 451 | University of UlmOTHER | 2 | Jun 4, 2020 | clinicaltrials |
| NCT02835729 | A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT01159028 | Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS | completed | Phase 1 | 60 | Bio-Path Holdings, Inc.INDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02606825 | VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years | completed | — | 3,910 | PETHEMA FoundationOTHER | 1 | May 27, 2020 | clinicaltrials |
| NCT02779283 | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | completed | Phase 1 | 7 | OHSU Knight Cancer InstituteOTHER | 1 | May 26, 2020 | clinicaltrials |
| NCT03661515 | Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML(FLAGINEXOR) | completed | Phase 1 | 16 | PETHEMA FoundationOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT01839240 | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT01370213 | NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases | completed | Phase 2 | 25 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 13, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT00462761 | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status | completed | Phase 1 | 76 | Daiichi SankyoINDUSTRY | 2 | May 11, 2020 | clinicaltrials |
| NCT02560025 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02333058 | Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | completed | Phase 2 | 70 | medac GmbHINDUSTRY | 6 | May 4, 2020 | clinicaltrials |
| NCT01611298 | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR(TAR) | completed | N/A | 7 | Robert KranceOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT01252667 | Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 44 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 16, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2020source: clinicaltrials